gallimune se + st
boehringer ingelheim animal health france scs, 29 avenue tony garnier, 69007 lyon, francuska - inaktivirana salmonella enteritidis, soj pt4 ; inaktivirana salmonella typhimurium, soj dt 104 - emulzija za injekciju tipa voda u ulju - imunološki pripravci za domaću perad, inaktivirana bakterijska cjepiva (uključujući mikoplazme, toksoide i klamidije), salmonella - kokoši (pilenke rasplodnih i konzumnih nesilica)
m+pac
intervet international b.v., podružnica u republici hrvatskoj, ivana lučića 2a, 10000 zagreb, hrvatska - mycoplasma hyopneumoniae, inaktivirana - emulzija za injekciju - imunološki vmp - svinja (svinja za tov od 7. dana života do kraja tova)
rotateq ≥ 2.2 megainfektivna jedinica/1 doza+ ≥ 2.8 megainfektivna jedinica/1 doza+ ≥ 2.2 megainfektivna jedinica/1 doza+ ≥ 2 me
merck sharp & dohme bh d.o.o. - virus rota, petovalentni drugarima, živi, "reassorted" - oralni rastvor - ≥ 2.2 megainfektivna jedinica/1 doza+ ≥ 2.8 megainfektivna jedinica/1 doza+ ≥ 2.2 megainfektivna jedinica/1 doza+ ≥ 2 megainfekt - jedna doza (2 ml) oralnog rastvora sadrži: Živi rotavirus serotipa g1 ne manje od 2,2 x 106 iu Živi rotavirus serotipa g2 ne manje od 2,8 x 106 iu Živi rotavirus serotipa g3 ne manje od 2,2 x 106 iu Živi rotavirus serotipa g4 ne manje od 2,0 x 106 iu Živi rotavirus serotipa p1a (8) ne manje od 2,3 x 106 iu
atioprin 50 mg/1 tableta filmom obložena tableta
pharmaswiss bh d.o.o. - azatioprin - filmom obložena tableta - 50 mg/1 tableta - 1 filmom obložena tableta sadrži: 50 mg azatioprina
metilprednizolon normon 40 mg/1 ml prašak i rastvarač za rastvor za injekciju
medimpex d.o.o. - metilprednizolon - prašak i rastvarač za rastvor za injekciju - 40 mg/1 ml - 1 bočica sa praškom sadrži: 40 mg metilprednizolona u obliku metilprednizolon natrijum sukcinata; 1 ampula sa rastvaračem sadrži: 1 ml vode za injekciju
blitzima (▼) 10 mg/1 ml koncentrat za otopinu za infuziju
oktal pharma d.o.o. sarajevo - rituksimab - koncentrat za otopinu za infuziju - 10 mg/1 ml - 1 ml koncentrata za otopinu za infuziju sadrži: 10 mg rituksimaba
ocrevus (▼) 300 mg/10 ml koncentrat za otopinu za infuziju
roche d.o.o.roche ltd. - okrelizumab - koncentrat za otopinu za infuziju - 300 mg/10 ml - 1 bočica sa 10 ml koncetrata za otopinu za infuziju sadrži: 300 mg okrelizumaba (30 mg/1 ml)
acellbia, 500 mg /50 ml, koncentrat za otopinu za infuziju (▼) 10 mg/1 ml koncentrat za otopinu za infuziju
icm d.o.o. bijeljina - rituksimab - koncentrat za otopinu za infuziju - 10 mg/1 ml - 1 ml koncentrata za rastvor za infuziju sadrži: 10 mg rituksimaba
acellbia, 100 mg/10 ml, koncentrat za otopinu za infuziju 10 mg/1 ml koncentrat za otopinu za infuziju
co.medprom d.o.o. banja luka - rituksimab - koncentrat za otopinu za infuziju - 10 mg/1 ml - 1 ml koncentrata za rastvor za infuziju sadrži: 10 mg rituksimaba
jayempi
nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.